BDSX Biodesix

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a . The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on gathered through a third-party survey, administered by employee engagement technology partner, .

The confidential survey uniquely measures the employee experience and its component themes, including employees feeling respected & supported, enabled to grow, and empowered to execute, to name just a few key attributes of a top-performing workplace.

“I want to first recognize each of the Biodesix team members for their direct contributions in cultivating our high performing and fulfilling workplace culture,” said Scott Hutton, CEO & President of Biodesix, Inc. “As one of only 150 companies to earn this recognition, it reinforces that Biodesix is an employer of choice and reflects our team’s enthusiasm to continue building our unique culture. Thank you again to the team for their commitment to excellence in serving our healthcare customers, their patients, and our industry partners as we continue driving towards the Biodesix mission and vision.”

This is the company’s second consecutive year being recognized as a great place to work through comprehensive anonymous employee surveys on critical themes measuring employee engagement and workplace culture. Last year, Biodesix received the prestigious award.

“In today's market, leaders must ensure they’re cultivating a workplace where employees have a voice, and they are heard. Earning a Top Workplaces award is an exclusive badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That's something to be very proud of.”

ABOUT BIODESIX

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences tools and diagnostics companies, and academic research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information on our culture and operating principles (Team, Impact, Excellence), please see our website:

ABOUT ENERGAGE

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. For more information, visit or .

Contacts:

Media:

Natalie St. Denis, Director Corporate Communications, Biodesix



+1 (720) 925-9285

Investors:

Chris Brinzey, Partner, Westwicke Group



+1 (339) 970-2843



EN
14/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Hig...

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "B...

 PRESS RELEASE

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences: TD Cowen's 46th Annual Health Care ConferenceFireside Chat Date: Tuesday, March 3, 2026Fireside Chat Time: 2:30 PM ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date: Wednesday, March 11, 2026Fireside Chat Time: 12:00 PM ETLocation: Miami, FL The fireside chats will be...

 PRESS RELEASE

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results...

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Anal...

 PRESS RELEASE

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Resul...

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining t...

 PRESS RELEASE

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagn...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch